Saad Ghumman, MD
Interventional Cardiology · Charlottesville, VANPI 1356723373
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,664 of the $16,531 with a category attached, or 64.5%. 32 manufacturers reported payments, led by Abbott at 41.0% of the total. 2025 is the largest year on record at $5,480, more than ten times the $512 reported in 2021.
Across 315 payments — averaging $52.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Penumbra, Inc.$3K
- Inari Medical, Inc.$1K
- Novartis$855
- Shockwave Medical, Inc$839
- Abiomed$697
- plus $4K from 26 others
What the payments were for
- Travel & lodging$5,86735%
- Food & beverage$10,66465%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 82 | $6,772 |
| Penumbra, Inc. | 12 | $2,582 |
| Inari Medical, Inc. | 25 | $1,199 |
| Novartis | 52 | $855 |
| Shockwave Medical, Inc | 26 | $839 |
| Abiomed | 15 | $697 |
| Boston Scientific | 14 | $690 |
| Philips North America LLC | 10 | $338 |
| Medtronic | 6 | $333 |
| Cardiovascular Systems Inc. | 5 | $328 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $279 |
| Cvrx, Inc. | 2 | $222 |
| Acist Medical Systems, Inc. | 1 | $170 |
| Amgen | 10 | $169 |
| Pfizer | 9 | $166 |
| Cardiva Medical, Inc. | 5 | $113 |
| Atricure, Inc. | 6 | $108 |
| Biotronik Inc. | 1 | $101 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84 |
| Teleflex LLC | 3 | $74 |
| AstraZeneca | 5 | $74 |
| Daiichi Sankyo Inc. | 3 | $71 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Stryker | 2 | $39 |
| Surmodics, Inc. | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Lexicon Pharmaceuticals, Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Asahi Intecc USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$2,379
- Ultreon$1,987
- XIENCE SKYPOINT$1,794
- SUPERA$887
- FLOWTRIEVER CATHETER, S$588
- CT THROMBECTOMY SYSTEM KIT$588
- OPTIS$290
- Diamondback Coronary$281
- Barostim Neo System$192
- GENERAL PAIN MANAGEMENT$186
- CVI SYSTEMS$170
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$155
- SYMPLICITY G3$146
- Impella$143
- AVVIGO Guidance System$140
- COROFLOW$136
- GENERAL ULTRASOUND$126
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$114
- Micra$114
- Orsiro Mission$101
How this compares
$16,531 in reported general payments places this provider in the 80th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 286 | $224,410 |
| EntrestoSacubitril/Valsartan | 80 | $69,787 |
| JardianceEmpagliflozin | 55 | $39,635 |
| Repatha SureclickEvolocumab | 49 | $36,889 |
| XareltoRivaroxaban | 37 | $26,741 |
| BrilintaTicagrelor | 23 | $23,700 |
| FarxigaDapagliflozin Propanediol | 20 | $11,740 |
| Praluent PenAlirocumab | 13 | $6,247 |
| Ranolazine ErRanolazine | 40 | $2,691 |
| Metoprolol Succinate | 263 | $2,494 |
| Rosuvastatin Calcium | 262 | $2,251 |
| Nitroglycerin | 115 | $2,193 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 193 | $1,965 |
| Atorvastatin Calcium | 95 | $1,158 |
| Metoprolol Tartrate | 142 | $837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $166 | $224,410286 claims |
| NovartisEntresto | $855 | $69,78780 claims |
| AstraZenecaBrilinta, Farxiga | $74 | $35,44143 claims |
| Johnson & JohnsonXarelto | $17 | $26,74137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Charlottesville
- Angela TaylorCharlottesville$119K
- John SaxonCharlottesville$116K
- Michael RagostaCharlottesville$17K
- Kanwar SinghCharlottesville$15K
- Deepak TalrejaVirginia Beach$1.5M
- Rajiv TayalFredericksburg$984K
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Noah JonesFalls Church$238K
- Michael GenVirginia Beach$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.